Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
scientific article published on 12 September 2018
Author/s
author: Claus Garbe, Vanna Chiarion Sileni, Paolo Antonio Ascierto, Keith Flaherty, Helen Gogas, Caroline Dutriaux, Carmen Loquai, Gabriella Liszkay, Ralf Gutzmer, Mario Mandala, Dirk Schadendorf, Ana Arance, Reinhard Dummer, Laure A Moutouh-de Parseval
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.